Results 1 to 10 of about 29,994 (144)

KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?

open access: yesCells, 2022
Background: KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinoma (PDAC), one of the leading global causes of cancer death.
Henry Shen   +7 more
doaj   +1 more source

Use of DNA‐alkylating pyrrole‐imidazole polyamides for anti‐cancer drug sensitivity screening in pancreatic ductal adenocarcinoma

open access: yesCancer Medicine, 2023
Background Activating mutations of the KRAS occurs in >90% of pancreatic ductal adenocarcinoma (PDAC) cases. However, direct pharmacological targeting of the activated KRAS protein has been challenging.
Akiko Tsujimoto   +10 more
doaj   +1 more source

Somatic mutation analysis of Mesonephric-Like adenocarcinoma and associated putative precursor Lesions: Insight into pathogenesis and potential molecular treatment targets

open access: yesGynecologic Oncology Reports, 2022
Aims: Mesonephric-like adenocarcinoma (MLA) is a recently described histologic tumor subtype of the Müllerian tract. MLA can arise in association with Müllerian lesions that share common mutations.
Elizabeth Arslanian   +3 more
doaj   +1 more source

The current understanding of KRAS protein structure and dynamics

open access: yesComputational and Structural Biotechnology Journal, 2020
One of the most common drivers in human cancer is the mutant KRAS protein. Not so long ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however, we finally see some light at the end of the tunnel as promising KRAS targeted ...
Tatu Pantsar
doaj   +1 more source

Correlation of miR-31 and miR-373 expression with KRAS mutations and its impact on prognosis in colorectal cancer

open access: yesJournal of the Egyptian National Cancer Institute, 2022
Introduction Colorectal cancers (CRC) are among the most common cancers. There are different modalities for treatment including chemotherapy, surgery, and radiotherapy.
Hasan Ashoori   +3 more
doaj   +1 more source

Involvement of ras p2I in Neurotrophin-induced Response of Sensory, but Not Sympathetic Neurons [PDF]

open access: yes, 1993
Little is known about the signal transduction mechanisms involved in the response to neurotrophins and other neurotrophic factors in neurons, beyond the activation of the tyrosine kinase activity of the neurotrophin receptors belonging to the trk family.
Barde, Y. A.   +4 more
core   +3 more sources

Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. [PDF]

open access: yes, 2015
BackgroundKey effector(s) of mutated KRAS in lung cancer progression and metastasis are unknown. Here we investigated the role of PAK1/Crk axis in transduction of the oncogenic KRAS signal in non-small cell lung cancer (NSCLC).MethodsWe used NSCLC ...
Aljilani, Amir   +7 more
core   +2 more sources

Ras p21 protein promotes survival and fiber outgrowth of cultured embryonic neurons [PDF]

open access: yes, 1989
Although evidence obtained with the PC12 cell line has suggested a role for the ras oncogene proteins in the signal transduction of nerve growth factor-mediated fiber outgrowth, little is known about the signal transduction mechanisms involved in the ...
Barde, Y. A.   +5 more
core   +2 more sources

Fitness of unregulated human Ras mutants modeled by implementing computational mutagenesis and machine learning techniques

open access: yesHeliyon, 2019
Ras proteins play a pivotal role as oncogenes by participating in diverse signaling events, including those linked to cell growth, differentiation, and proliferation.
Majid Masso   +4 more
doaj   +1 more source

Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts [PDF]

open access: yes, 2011
:Scleroderma (systemic sclerosis; SSc) is a clinically heterogeneous and often lethal acquired disorder of the connective tissue that is characterized by vascular, immune/inflammatory and fibrotic manifestations.
Armando Gabrielli   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy